PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions

TG Therapeutics, Inc. (TGTX)

Equity · Currency in USD · Last updated Dec 7, 2023
SummaryFinancials

Company Info

ISINUS88322Q1085
CUSIP88322Q108
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$2.17B
EPS-$0.19
Revenue (TTM)$189.77M
Gross Profit (TTM)$2.52M
EBITDA (TTM)-$18.70M
Year Range$6.46 - $35.67
Target Price$26.83
Short %29.77%
Short Ratio4.52

Share Price Chart


Loading data...

Performance

The chart shows the growth of an initial investment of $10,000 in TG Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-39.07%
6.61%
TGTX (TG Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with TGTX

TG Therapeutics, Inc.

Popular comparisons: TGTX vs. QQQ, TGTX vs. QQQM

Return

TG Therapeutics, Inc. had a return of 39.05% year-to-date (YTD) and 96.54% in the last 12 months. Over the past 10 years, TG Therapeutics, Inc. had an annualized return of 14.78%, outperforming the S&P 500 benchmark which had an annualized return of 9.70%.


PeriodReturnBenchmark
Year-To-Date39.05%18.49%
1 month60.49%4.20%
6 months-39.07%6.60%
1 year96.54%15.43%
5 years (annualized)26.99%11.59%
10 years (annualized)14.78%9.70%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
20237.25%-6.72%-16.71%-49.40%-20.15%-7.54%65.72%

Risk-Adjusted Performance

This table presents a comparison of risk-adjusted performance metrics for TG Therapeutics, Inc. (TGTX) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
TGTX
TG Therapeutics, Inc.
0.99
^GSPC
S&P 500
1.00

Sharpe Ratio

The current TG Therapeutics, Inc. Sharpe ratio is 0.99. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.


Rolling 12-month Sharpe Ratio0.001.002.003.004.005.00JulyAugustSeptemberOctoberNovemberDecember
0.99
1.00
TGTX (TG Therapeutics, Inc.)
Benchmark (^GSPC)

Dividend History


TG Therapeutics, Inc. doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-70.04%
-5.15%
TGTX (TG Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the TG Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the TG Therapeutics, Inc. was 93.19%, occurring on Jun 16, 2022. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-93.19%Dec 22, 2020373Jun 16, 2022
-81.72%Mar 20, 2015949Dec 24, 2018343May 6, 20201292
-53.86%Jul 18, 201387Nov 18, 201371Mar 5, 2014158
-40.58%Mar 17, 201442May 14, 201420Jun 12, 201462
-33.42%Jul 7, 201420Aug 1, 201432Sep 17, 201452

Volatility Chart

The current TG Therapeutics, Inc. volatility is 20.78%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%JulyAugustSeptemberOctoberNovemberDecember
20.78%
2.92%
TGTX (TG Therapeutics, Inc.)
Benchmark (^GSPC)